Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

EUDA Health Limited develops digital health platform that offers virtual consults for non-emergency medical issues. The company was founded in 2019 and is based in Singapore. EUDA Health Limited company operates as a subsidiary of Watermark Developments Limited.

EUDA Health Holdings Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SINGAPORE, JULY 30, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) A SINGAPORE-BASED DISTRIBUTOR OF THIRD-PARTY PROVIDED WELLNESS AND NON-INVASIVE HEALTHCARE PRODUCTS AND SERVICES IN ASIA, WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, TODAY PROVIDED IMPORTANT ADDITIONAL DETAILS OF THE INTEGRATED CELL THERAPY PROGRAM TO BE PURSUED UNDER ITS RECENTLY ANNOUNCED NON-BINDING MEMORANDUM OF UNDERSTANDING (MOU) WITH GO POSB ORGANOIDS PTE LTD (GO POSB) AND SHENZHEN INNOVATION IMMUNOTECHNOLOGY CO., LTD. (SIIT).

EUDA HEALTH ANNOUNCES COLLABORATION TO ADVANCE AN INTEGRATED IPSC CELL THERAPY PROGRAM FOR ONCOLOGY AND WELLNESS  TARGETS GLOBAL DISTRIBUTION FOR INNOVATIVE ONCOLOGY PRODUCTS

SINGAPORE, JULY 30, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) A SINGAPORE-BASED DISTRIBUTOR OF THIRD-PARTY PROVIDED WELLNESS AND NON-INVASIVE HEALTHCARE PRODUCTS AND SERVICES IN ASIA, WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, TODAY PROVIDED IMPORTANT ADDITIONAL DETAILS OF THE INTEGRATED CELL THERAPY PROGRAM TO BE PURSUED UNDER ITS RECENTLY ANNOUNCED NON-BINDING MEMORANDUM OF UNDERSTANDING (MOU) WITH GO POSB ORGANOIDS PTE LTD ("GO POSB") AND SHENZHEN INNOVATION IMMUNOTECHNOLOGY CO.

EUDA HEALTH ANNOUNCES COLLABORATION TO ADVANCE AN INTEGRATED IPSC CELL THERAPY PROGRAM FOR ONCOLOGY AND WELLNESS    TARGETS GLOBAL DISTRIBUTION FOR INNOVATIVE ONCOLOGY PRODUCTS

SINGAPORE, JULY 28, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) A SINGAPORE-BASED DISTRIBUTOR OF THIRD-PARTY PROVIDED WELLNESS AND NON-INVASIVE HEALTHCARE PRODUCTS AND SERVICES IN ASIA, WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED THAT IT HAS SIGNED A MEMORANDUM OF UNDERSTANDING ("MOU") WITH GO POSB ORGANOIDS PTE LTD ("GO POSB") AND SHENZHEN INNOVATION IMMUNOTECHNOLOGY CO.

EUDA HEALTH SIGNS IMPORTANT TRI-PARTY MEMORANDUM OF UNDERSTANDING WITH GO POSB ORGANOIDS AND SHENZHEN INNO TO SIGNIFICANTLY ADVANCE NEXT-GENERATION IPSC AND NK-TCR CELL THERAPIES

SINGAPORE, JUNE 01, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) ("EUDA" OR THE "COMPANY"), A SINGAPORE-BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED IT IS EXPANDING THE HELIX PRODUCT LINE WITH THE LAUNCH OF THE REGENIX IPSC-DERIVED SKIN STEM CELL SECRETOME MASK ("REGENIX MASK"), A BEAUTY PRODUCT DEVELOPED BY CHEMOKINE PTE LTD ("CHEMOKINE").

EUDA HEALTH EXPANDS HELIX PRODUCT LINE WITH LAUNCH OF REGENIX IPSC-DERIVED SKIN STEM CELL SECRETOME MASK

SINGAPORE, JUNE 01, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED ("EUDA" AND THE "COMPANY"), A SINGAPORE-BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, RECEIVED A WRITTEN NOTICE (THE "MVLS NOTICE") FROM LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET ("NASDAQ") ON APRIL 23, 2026, INDICATING THAT THE COMPANY HAD FAILED TO MAINTAIN A MINIMUM MARKET VALUE OF LISTED SECURITIES ("MVLS") OF $35 MILLION OVER THE LAST 32 CONSECUTIVE BUSINESS DAYS AS REQUIRED BY THE NASDAQ LISTING RULE 5550(B)(2).

EUDA HEALTH REGAINS COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS AFTER RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM MARKET VALUE DEFICIENCY

SINGAPORE, APRIL 28, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) (EUDA OR THE COMPANY), A SINGAPORE-BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA WITH A FOCUS ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED THAT SHENZHEN INNO IMMUNE CO., LTD. (SHENZHEN INNO), A DEVELOPER OF CELLULAR THERAPIES IN CHINA, HAS RECEIVED OFFICIAL APPROVAL UNDER THE 2025 SHENZHEN KEY INDUSTRY R&D PROGRAM.

EUDA HIGHLIGHTS SHENZHEN INNO'S APPROVAL UNDER SHENZHEN KEY INDUSTRY R&D PROGRAM FOR TCR-T CELL THERAPY DEVELOPMENT

SINGAPORE, APRIL 27, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED ("EUDA" AND THE "COMPANY") RECEIVED A WRITTEN NOTICE (THE "MVLS NOTICE") FROM LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET ("NASDAQ") ON APRIL 23, 2026, INDICATING THAT THE COMPANY HAD FAILED TO MAINTAIN A MINIMUM MARKET VALUE OF LISTED SECURITIES ("MVLS") OF $35 MILLION OVER THE LAST 32 CONSECUTIVE BUSINESS DAYS AS REQUIRED BY THE NASDAQ LISTING RULE 5550(B)(2).

EUDA HEALTH HOLDINGS LIMITED HAS RECEIVED NOTICE FROM NASDAQ THAT IT HAS FAILED TO MAINTAIN A MINIMUM MARKET VALUE OF ITS LISTED SECURITIES

SINGAPORE, MARCH 19, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) (EUDA OR THE COMPANY), A SINGAPORE BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA FOCUSED ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED THAT IT WILL IMPLEMENT A REVERSE STOCK SPLIT OF ITS ORDINARY SHARES AT A RATIO OF 1-FOR-20 (THE REVERSE STOCK SPLIT). THE REVERSE STOCK SPLIT WAS APPROVED BY THE COMPANY'S BOARD OF DIRECTORS IN ACCORDANCE WITH BRITISH VIRGIN ISLANDS LAW. THE REVERSE STOCK SPLIT WILL TAKE EFFECT AT MARKET OPEN ON MARCH 23, 2026, AND THE ORDINARY SHARES WILL TRADE ON A POST-SPLIT BASIS ON THE NASDAQ CAPITAL MARKET UNDER THE COMPANY'S EXISTING TRADING SYMBOL EUDA AND WILL CONTINUE TO TRADE UNDER THAT SYMBOL. THE NEW CUSIP NUMBER FOR EUDA'S ORDINARY SHARES FOLLOWING THE REVERSE STOCK SPLIT WILL BE G3142E147.

EUDA ANNOUNCES REVERSE STOCK SPLIT OF ITS ORDINARY SHARES

SINGAPORE, MARCH 04, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) (EUDA OR THE COMPANY), A SINGAPORE BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA FOCUSED ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED THAT IT HAS REPURCHASED AND CANCELLED IN FULL THE WARRANT PREVIOUSLY ISSUED TO STREETERVILLE CAPITAL, LLC.

EUDA HEALTH HOLDINGS LIMITED ANNOUNCES REPURCHASE AND CANCELLATION OF STREETERVILLE WARRANT

SINGAPORE, JAN. 13, 2026 (GLOBE NEWSWIRE) -- EUDA HEALTH HOLDINGS LIMITED (NASDAQ: EUDA) (EUDA OR THE COMPANY), A SINGAPORE BASED NON-INVASIVE HEALTHCARE PROVIDER IN ASIA FOCUSED ON SINGAPORE, MALAYSIA AND CHINA, TODAY ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY, EUDA HEALTH PTE. LTD. (EUDA HEALTH), HAS ENTERED INTO A CONVERTIBLE LOAN AGREEMENT WITH SHENZHEN INNO IMMUNE CO., LTD. (SHENZHEN INNO), A DEVELOPER OF AUTOLOGOUS CELLULAR THERAPEUTICS AND CUSTOMISED MEDICINES FOR A WIDE RANGE OF DISEASES IN CHINA.

EUDA Health Holdings Limited

EUDA

Price

Financial Reports

No items found.

Press Releases

EUDA Health Holdings Limited

EUDA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

EUDA